The GR‐ANXA1 pathway is a pathological player and a candidate target in epilepsy
- 16 October 2019
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 33 (12) , 13998-14009
Abstract
Immune changes occur in experimental and clinical epilepsy. Here, we tested the hypothesis that during epileptogenesis and spontaneous recurrent seizures (SRS) an impairment of the endogenous anti‐inflammatory pathway glucocorticoid receptor (GR)‐annexin A1 (ANXA1) occurs. By administrating exogenous ANXA1, we studied whether pharmacological potentiation of the anti‐inflammatory response modifies seizure activity and pathophysiology. We used an in vivo model of temporal lobe epilepsy based on intrahippocampal kainic acid (KA) injection. Video‐electroencephalography, molecular biology analyses on brain and peripheral blood samples, and pharmacological investigations were performed in this model. Human epileptic cortices presenting type II focal cortical dysplasia (IIa and b), hippocampi with or without hippocampal sclerosis (HS), and available controls were used to study ANXA1 expression. A decrease of phosphorylated (phospho‐) GR and phospho‐GR/tot‐GR protein expression occurred in the hippocampus during epileptogenesis. Downstream to GR, the anti‐inflammatory protein ANXA1 remained at baseline levels while inflammation installed and endured. In peripheral blood, ANXA1 and corticosterone levels showed no significant modifications during disease progression except for an early and transient increase poststatus epilepticus. These results indicate inadequate ANXA1 engagement over time and in these experimental conditions. By analyzing human brain specimens, we found that where significant inflammation exists, the pattern of ANXA1 immunoreactivity was abnormal because the typical perivascular ANXA1 immunoreactivity was reduced. We next asked whether potentiation of the endogenous anti‐inflammatory mechanism by ANXA1 administration modifies the disease pathophysiology. Although with varying efficacy, administration of exogenous ANXA1 somewhat reduced the time spent in seizure activity as compared to saline. These results indicate that the anti‐inflammatory GR‐ANXA1 pathway is defective during experimental seizure progression. The prospect of pharmacologically restoring or potentiating this endogenous anti‐inflammatory mechanism as an add‐on therapeutic strategy for specific forms of epilepsy is proposed.—Zub, E., Canet, G., Garbelli, R., Blaquiere, M., Rossini, L., Pastori, C., Sheikh, M., Reutelingsperger, C., Klement, W., de Bock, F., Audinat, E., Givalois, L., Solito, E., Marchi, N. The GR‐ANXA1 pathway is a pathological player and a candidate target in epilepsy. FASEB J. 33, 13998‐14009 (2019). www.fasebj.orgKeywords
Funding Information
- Fondazione Italiana Sclerosi Multipla (2014/R/21)
- British Heart Foundation
- Université de Montpellier
This publication has 39 references indexed in Scilit:
- Annexin Peptide Ac2-26 Suppresses TNFα-Induced Inflammatory Responses via Inhibition of Rac1-Dependent NADPH Oxidase in Human Endothelial CellsPLOS ONE, 2013
- Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood–brain barrier leakage but not microglia activationEpilepsia, 2012
- Inflammation and epilepsy2012
- Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant EpilepticsPLOS ONE, 2011
- The role of inflammation in epilepsyNature Reviews Neurology, 2010
- The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disordersPsychoneuroendocrinology, 2009
- Annexin-1 Regulates Macrophage IL-6 and TNF via Glucocorticoid-Induced Leucine ZipperThe Journal of Immunology, 2009
- Annexin A1 and glucocorticoids as effectors of the resolution of inflammationNature Reviews Immunology, 2009
- Steroids in intractable childhood epilepsy: Clinical experience and review of the literatureSeizure: European Journal of Epilepsy, 2005
- Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen‐induced arthritisArthritis & Rheumatism, 2004